RWA Wealth Partners LLC Makes New Investment in Moderna, Inc. (NASDAQ:MRNA)

RWA Wealth Partners LLC acquired a new position in shares of Moderna, Inc. (NASDAQ:MRNA) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 2,211 shares of the company’s stock, valued at approximately $220,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in MRNA. First Pacific Financial bought a new stake in Moderna during the 3rd quarter worth approximately $27,000. Arlington Trust Co LLC grew its holdings in shares of Moderna by 4,833.3% in the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after acquiring an additional 290 shares in the last quarter. GPS Wealth Strategies Group LLC grew its holdings in shares of Moderna by 54.1% in the third quarter. GPS Wealth Strategies Group LLC now owns 513 shares of the company’s stock valued at $53,000 after acquiring an additional 180 shares in the last quarter. Archer Investment Corp grew its holdings in shares of Moderna by 71.2% in the third quarter. Archer Investment Corp now owns 534 shares of the company’s stock valued at $55,000 after acquiring an additional 222 shares in the last quarter. Finally, Parkside Financial Bank & Trust grew its holdings in shares of Moderna by 44.9% in the third quarter. Parkside Financial Bank & Trust now owns 565 shares of the company’s stock valued at $58,000 after acquiring an additional 175 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, insider Shannon Thyme Klinger sold 544 shares of the stock in a transaction on Friday, March 8th. The stock was sold at an average price of $99.05, for a total value of $53,883.20. Following the transaction, the insider now owns 9,267 shares of the company’s stock, valued at $917,896.35. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, President Stephen Hoge sold 2,388 shares of the stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $225,833.16. Following the transaction, the president now owns 1,515,898 shares of the company’s stock, valued at $143,358,473.86. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Shannon Thyme Klinger sold 544 shares of the stock in a transaction on Friday, March 8th. The shares were sold at an average price of $99.05, for a total value of $53,883.20. Following the completion of the transaction, the insider now directly owns 9,267 shares in the company, valued at approximately $917,896.35. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 124,954 shares of company stock worth $13,158,776. Corporate insiders own 15.70% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. HSBC reaffirmed a “reduce” rating and issued a $86.00 target price (up from $75.00) on shares of Moderna in a report on Monday, February 26th. Canaccord Genuity Group increased their price objective on Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a report on Friday, February 23rd. Jefferies Financial Group reissued a “buy” rating and set a $125.00 price objective on shares of Moderna in a report on Tuesday, April 9th. William Blair reissued a “market perform” rating on shares of Moderna in a report on Monday, April 1st. Finally, Needham & Company LLC reissued a “hold” rating on shares of Moderna in a report on Thursday, April 11th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $126.49.

Moderna Trading Up 1.7 %

Shares of MRNA stock opened at $107.97 on Friday. The company has a current ratio of 3.42, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $142.79. The business’s fifty day moving average is $102.54 and its 200 day moving average is $93.77.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $1.33. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The company had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.53 billion. During the same quarter last year, the business posted $3.61 earnings per share. The firm’s revenue was down 44.9% compared to the same quarter last year. Equities research analysts forecast that Moderna, Inc. will post -7.51 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.